Optimization-By-Design - A Critical Factor In Successful Viral Vector Scale Up

Many challenges can stall an advanced therapy’s development, often tied to inadequate preclinical planning and process development. Drug developers can prevent issues before they arise and avoid the rework and delays that can negatively impact timelines and derail development. By incorporating best practices such as Design of Experiment (DoE), process development can be streamlined and optimized using systematic methodology to estimate variable interactions and thereby reduce the number of experimental trials required. DoE can have a direct impact on process development for the complex manufacturing projects in AAV gene therapy applications.

Finding capable partners with the requisite expertise to optimize AAV processes using DoE can be important in reducing variability and risk. Please join Andelyn and Polyplus for this webinar in which we will discuss key considerations for taking your advanced therapy from concept to commercialization with confidence.

Key learning objectives:

• AAV Manufacturing Platforms
• Optimization by Design
• Benefits of the DoE Approach including selected case studies